Searchable abstracts of presentations at key conferences in endocrinology

ea0020s8.4 | Pituitary cell biology | ECE2009

Dual function of dopamine/somatostatin hybrid agonists

Saveanu Alexandru , Brue Thierry , Enjalber Alain , Jaquet Philippe , Barlier Anne

Somatostatin acts as an inhibitor of hormonal secretion and cell proliferation by acting through 5 somatostatin receptors subtypes (sst1–5). Coupling with Gi/o proteins is associated with effects on various transduction pathways, as adenylate cyclase inhibition or phosphatases activation. Dopamine receptor subtype 2 (D2DR) acts through coupling with similar G-proteins and transduction pathways. Sst, mostly sst2 and sst5, are coexpressed with D2DR in many neuroendocrine no...

ea0020p678 | Signal Transduction | ECE2009

The MAPKinases ERK1/2 take centre stage in somatotroph physiopathology

Pertuit Morgane , Romano David , Barlier Anne , Enjalbert Alain , Gerard Corinne

Somatotroph pituitary adenomas are characterized by unrestrained hormone secretion and cell proliferation alterations. In those tumors, the only mutation so far unequivocally identified is the gsp oncogene (Gsα protein gain of function mutation). Nethertheless, there is no clear difference in the clinical phenotypes of patients bearing tumor with the gsp oncogene (gsp+) or not (gsp−). In addition, an overexpression of the wild-type Gsα protein has been o...

ea0014s19.3 | Pituitary cell biology | ECE2007

Oncogene gsp and Gsα overexpression in pituitary cell biology

Barlier Anne , Gérard Corinne , Alain Enjalbert

Somatic mutations of the αs subunit of G proteins were initially reported by Landis and collaborators in 1989 in somatotroph tumors characterized by markedly high cAMP levels. These mutations are localized at two critical sites concerning the intrinsic guanosine triphosphatase activity of the protein leading to a constitutive activation of the adenylyl cyclase. The mutated protein has been named the gsp oncogene. On the other hand, Gsα mRNA level varied among ...

ea0081rc6.2 | Rapid Communications 6: Endocrine-Related Cancer | ECE2022

Reciprocal interactions between fibroblast and pancreatic neuroendocrine tumor cells: putative impact of the tumor microenvironment

Cuny Thomas , Mondielli Gregoire , van Koetsveld Peter , de Herder Wouter , Barlier Anne , Hofland Leo

Introduction: Pancreatic neuroendocrine neoplasms (PNEN) present with a fibrotic stroma which constitutes the tumor microenvironment (TME). The role played by stromal fibroblasts over the growth of PNEN and their sensitivity to the mTOR inhibitor, RAD001, are as yet unestablished.Methods: We investigated reciprocal interactions between 1) human PNEN cell lines (BON-1/QGP-1) or primary cultures of human ileal neuroendocrine neoplasm (iNEN) or PNEN, and 2)...

ea0090p539 | Late-Breaking | ECE2023

Somatic RET M918T variant can modify the natural history of MEN2 related medullary thyroid carcinoma: a case report and literature review

Sahakian Nicolas , Romanet Pauline , Cinzia Paladino Nunzia , Mirebeau-Prunier Delphine , Castinetti Frederic , Barlier Anne

Background: Multiple endocrine neoplasia type 2 associated medullary thyroid carcinoma (MTC) is driven by a strong genotype-phenotype correlation, the risk of aggressiveness being defined by the germline RET pathogenic variant (American Thyroid Association (ATA) guidelines). Based on this classification, the germline c.2370G>C, p.Leu790Phe (L790F) RET variant is considered to be of moderate risk of aggressive MTC, while the germline c.2753T>C, p.Met918Thr (M9...

ea0063oc7.4 | Endocrine Connections 1 | ECE2019

Non-invasive detection of GNAS mutations causing McCune-Albright Syndrome with ddPCR on whole blood or circulating DNA

Romanet Pauline , Philibert Pascal , Fina Frederic , Cuny Thomas , Reynaud Rachel , Paris Francoise , Barlier Anne

Context: Postzygotic activating mutations in GNAS are responsive for fibrous dysplasia (FD) and McCune-Albright Syndrome (MAS). MAS is a rare disease associating fibrous dysplasia, to skin pigmentation and endocrine disorders. The classic genetic non-invasive methods are insufficiently sensitive to detect GNAS mutation, due to a low level of mosaicism in blood. Early diagnostic should allow a follow-up and a therapeutic choice adapted to the MAS context in or...

ea0032s11.3 | New mechanisms in SST analogue response | ECE2013

Role of ERK in somatostatin receptor signalling

Barlier Anne , Romano David , Zeiller Caroline , Roche Cathy , Pertuit Morgane , Gerard Corinne

The Ras/Raf/MEK/ERK is a conserved signalling pathway involved in the control of fundamental cellular processes. Despite extensive research, how this pathway can process a myriad of diverse extracellular inputs into specific biological outcomes is not fully understood. Particularly, the role of this pathway in neuroendocrine tumoral cells remains unclear.We have previously shown that the ERK1/2 pathway is an integrative point in the control of the pituit...

ea0032p334 | Developmental Endocrinology | ECE2013

Somatostatin receptor sst2 transfer in somatolactotroph cell line. Constitutive activity and drug sensitivity

Roche Catherine , Graillon Thomas , Rasolonjanahary Ramahefarizo , Thirion Sylvie , Enjalbert Alain , Gerard Corinne , Barlier Anne

Somatostatin is a ubiquitous neuropeptidic inhibitor of various cellular functions including endocrine and exocrine secretion. Moreover, this peptide may control cell proliferation in normal and tumoral tissues. Somatostatin biological effects are mediated by five subtype of G protein-coupled receptor, sst1 through sst5. The somatostatin analogs have high affinity for sst2 receptor and the success of in vivo peptide therapy is correlated with high levels of sst2 in th...

ea0029oc8.6 | Bone | ICEECE2012

Simultaneous gain and loss of methylation at imprinted loci in a subset of patients with pseudohypoparathyroidism type 1b and GNAS epimutations

Maupetit-Mehouas S. , Azzi S. , Steunou V. , Reynes C. , Silve C. , Barlier A. , Netchine I. , Linglart A.

The majority of patients affected with pseudohypoparathyroidism type 1b (PHP-1b) display loss of imprinting (LOI) encompassing the GNAS locus responsible for decreased Gsa expression in target tissues and PTH resistance. In other imprinting disorders like Silver-Russell, Wiedemann-Beckwith syndromes or transient neonatal diabetes mellitus due to LOI of the imprinted 11p15 and 6q24 regions respectively, we and others have shown that the LOI may spread over to other imprinted lo...

ea0029p1428 | Pituitary Clinical | ICEECE2012

Low tumoral mRNA IGF2 might balance the mechanism of tumorigenesis in GH-secreting adenomas

Diaz A. , Barlier A. , Kral M. , Garcia F. , Paes de Lima A. , Manavela M. , Enjalbert A. , Bruno O.

Pituitary adenomas may show alterations of PI3K/Akt pathway. IGF2, binding the IGF1-R, is able to active it. LOI of IGF2 has been implicated in the pathogenesis of many tumours. Activation of PI3K produces phosphorylation of p27 and its cytoplasmic mislocalization. Loss of nuclear p27 was associated with worse prognosis. In this study we correlated IGF2 imprinting with activation of PI3K/Akt pathway in a series of 29 somatotropinomas. After surgery, tumors were embedded in RNA...